Aura Biosciences, Inc. Segments Disclosure
15. Segment Reporting
Segment reporting is prepared on the same basis that the Company's , who is its chief operating decision maker, or CODM, manages the business and makes operating decisions to allocate resources across departments and functions in line with the Company's strategic goals. The Company operates in one reportable segment which includes all activities related to the research and development of ocular and urologic oncology targeted therapies for a range of cancer indications with high unmet medical need. The CODM assesses performance and allocates resources based on comparing actual consolidated net loss to the budget. The measure of segment assets used in determining how to manage and allocate resources is reported within the Company's consolidated balance sheets as cash and cash equivalents and marketable securities.
As a single reportable segment entity, the Company’s segment performance measure is consolidated net loss. Significant segment expenses are presented below.
|
|
Year Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Clinical, Preclinical, and R&D Operations (1) |
|
$ |
(63,154 |
) |
|
$ |
(49,550 |
) |
Chemistry, Manufacturing, and Controls (1) |
|
|
(27,145 |
) |
|
|
(23,752 |
) |
General and Administrative (1) |
|
|
(22,491 |
) |
|
|
(22,814 |
) |
Other Segment Items (2) |
|
|
6,599 |
|
|
|
9,197 |
|
Net loss |
|
$ |
(106,191 |
) |
|
$ |
(86,919 |
) |
(1) Includes depreciation expense directly allocated to respective activities.
(2) Other segment items primarily include interest and accretion income, realized gains and losses, and income taxes.
Want the next Aura Biosciences, Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Aura Biosciences, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.